SCHEMBL2361358

SCHEMBL2361358

CN1CCCN(c2cc(N3CCCC3=O)cc3c2OCC3)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.39
LMNA P02545 2/20 0.39
HTR6 P50406 1/20 0.38
DRD2 P14416 2/20 0.37
DRD4 P21917 2/20 0.37
HTR2A P28223 2/20 0.37
DRD3 P35462 2/20 0.37
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
BRPF1 P55201 1/20 0.35
DRD1 P21728 1/20 0.35
KDM4E B2RXH2 2/20 0.35
MAPK1 P28482 2/20 0.35
HTT P42858 2/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
RECQL P46063 1/20 0.35
PTK2B Q14289 1/20 0.35
ALDH1A1 P00352 2/20 0.34
GFER P55789 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2335075 0.96 HPGD (0.41) HPGDLMNAHTR6DRD2DRD4
SCHEMBL12444815 0.80 AKR1C3 (0.45) LMNAHTR6KMT2AKDM4EMAPK1
SCHEMBL12445146 0.75 LMNA (0.43) HPGDLMNAKMT2AMEN1KDM4E
SCHEMBL12444818 0.74 HTR6 (0.39) HPGDHTR6DRD2DRD4HTR2A
SCHEMBL2327923 0.73 MAPT (0.52) HPGDLMNAHTR6DRD2HTR2A
SCHEMBL6972009 0.73 DRD2 (0.44) HTR6DRD2DRD4HTR2ADRD3
SCHEMBL2327870 0.71 HPGD (0.43) HPGDLMNAHTR6KMT2AMEN1
SCHEMBL14717300 0.70 HPGD (0.50) HPGDLMNAKMT2AMEN1BRPF1
SCHEMBL27502417 0.69 KDM4E (0.51) HPGDHTR6DRD2DRD4HTR2A
SCHEMBL2325963 0.68 MAPT (0.55) HPGDLMNAHTR6DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130053372-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED 2013-02-28 US claimed
US-20130053372-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED 2013-02-28 US disclosed
US-20130053372-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED 2013-02-28 US disclosed
US-20130053372-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED 2013-02-28 US disclosed
EP-2536711-A1 5-HT RECEPTOR MODULATORS Cambridge Enterprise Limited (GB) 2012-12-26 EP disclosed
WO-2011098776-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2011-08-18 WO disclosed
WO-2011098776-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2011-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053372-A1 5-HT RECEPTOR MODULATORS HTR1B, HTR5A, HTR1A HPGD 643/4885LMNA 3961/4885HTR6 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.